重症肺炎患者地塞米松联合孟鲁司特钠治疗的有效性及对患者血清CRP、PCT水平的影响  

Effectiveness of dexamethasone combined with montelukast sodium in patients with severe pneumonia and its effect on serum CRP and PCT levels

作　　者：闫梅[1] 张雪梅 张成[1] YAN Mei;ZHANG Xuemei;ZHANG Cheng(Respiratory Department II,Affiliated Hospital of Jining Medical Universrry,Jining,Shandong 272000,China)

机构地区：[1]济宁医学院附属医院呼吸内二科,山东济宁272000

出　　处：《中国医学工程》2021年第10期69-72,共4页China Medical Engineering

摘　　要：目的探讨重症肺炎患者地塞米松联合孟鲁司特钠治疗的有效性及对患者血清C反应蛋白(CRP)、降钙素原(PCT)水平的影响。方法随机数字表法将2018年1月至2020年1月济宁医学院附属医院收治的60例重症肺炎患者分为两组,对照组行地塞米松治疗,研究组行地塞米松联合孟鲁司特钠治疗,比较两组患者治疗有效率、血清CRP、PCT、白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)、白细胞(WBC)、二氧化碳分压(PCO_(2))、氧分压(PO_(2))等水平变化及不良症状发生概率。结果研究组治疗效果优于对照组(P<0.05),治疗前患者血清指标及WBC、PCO_(2)、PO_(2)等水平比较,差异无统计学意义(P>0.05);干预后研究组患者CRP、PCT、IL-17、TNF-α、WBC、PCO_(2)等指标明显低于对照组(P<0.05),PO_(2)水平高于对照组(P<0.05),研究组不良反应率低于对照组(P<0.05)。结论重症肺炎患者行地塞米松治疗不良反应发生率较高,联合孟鲁司特钠治疗,缩短地塞米松用药时间,确保用药安全的同时提升治疗效果,患者血清CRP、PCT水平明显降低,为重症肺炎治疗提供新的治疗依据。【Objective】To investigate the effectiveness of dexamethasone combined with montelukast sodium in patients with severe pneumonia and its effect on serum CRP and PCT levels.【Methods】Sixty patients with severe pneumonia admitted to our hospital(January 2018 to January 2020)were divided into two groups by random number table.The control group received dexamethasone treatment,and the study group received dexamethasone combined with montelukast sodium.The effective rate of treatment,changes in serum CRP,PCT,IL-17,TNF-α,WBC,PCO_(2),and PO_(2)levels and the incidence of adverse symptoms were compared between the two groups.【Results】The treatment effect of the study group was better than that of the control group(P<0.05).There was no significant difference in the changes in serum indexes and WBC,PCO_(2),PO_(2)levels of patients before treatment(P>0.05);after treatment,CRP,PCT,IL-17,TNF-α,WBC,PCO_(2)and other indicators were significantly lower in the study group than in the control group(P<0.05),PO_(2)level was higher in the study group than in the control group(P<0.05),and the adverse reaction rate of the study group was lower than that of the control group(P<0.05).【Conclusion】Patients with severe pneumonia have a higher incidence of adverse reactions when treated with dexamethasone.Combined with montelukast sodium treatment,the time of dexamethasone administration is shortened,and the safety of medication is improved while the treatment effect is improved,the serum CRP and PCT levels of patients are significantly reduced,it provides a new treatment basis for the treatment of severe pneumonia.

关 键 词：重症肺炎 地塞米松 孟鲁司特钠 有效性 血清 CRP PCT 

分 类 号：R563.1[医药卫生—呼吸系统]